Spirometer Market Size Worth $1.7 Billion By 2027

The global spirometer market size is expected to reach USD 1.7 billion in 2027, according to a new report by Grand View Research, Inc. The market is expected to expanding at a CAGR of 9.7% from 2020 to 2027. The prevalence of chronic respiratory diseases is rising among adults as well as children across the globe. The guidelines for the diagnosis and treatment of asthma in children and the Global Initiative on Asthma (GINA) guidelines recommend the usage of spirometry more frequently for asthma. GINA published a 2020 update for Global Strategy for Asthma Management and Prevention, which includes information about asthma after reviewing the scientific literature and contains citations from the scientific literature.

Technological advancements are leading to the development of innovative spirometers. Manufacturers are involved in the launch of technologically advanced products. For instance, in March 2018, a Swedish startup, NuvoAir, launched a handheld spirometer called Air Next. These palm-size spirometers are specially designed for home use and use Bluetooth wireless technology.

Amid the COVID-19 pandemic, manufacturers are witnessing a boost in product demand from healthcare professionals as well as patients to monitor their lung functions at home. Technologically advanced respiratory health management companies have developed digital spirometers that enable patients to easily monitor their lung function. For instance, in April 2020, Aluna, a San Francisco-based company, launched its FDA-approved portable digital spirometer, helping patients monitor their lung health at home.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/spirometer-market

Further key findings from the study suggest:

Table top spirometers dominated the type segment in terms of revenue share in the year 2019 as the device is widely used in the diagnosis of obstructive airway disorders
Desktop spirometers are likely to witness the fastest growth over the forecast period as the computer-based spirometry supports in making enhanced clinical decisions based on integrated clinical information
The flow measurement technology segment dominated the market in terms of revenue share in 2019 due to extensive use in pulmonary function testing. Peak flow measurement spirometers are expected to register the fastest growth over the forecast period
Based on application, Chronic Obstructive Pulmonary Disease (COPD) held the majority of the market share in 2019 pertaining to the high prevalence of mild to severe COPD. Whereas the asthma segment is expected to grow at the fastest rate during the forecast period due to the increasing prevalence of the disease and high treatment cost
In the end-use segment, hospitals and clinics held the largest market share in 2019 due to the extensive use of spirometry for diagnosis and monitoring of chronic respiratory disorders. However, the home healthcare segment is likely to experience an impressive growth rate in the coming years due to the adoption of telemedicine and the launch of new products
North America dominated the market in terms of revenue share in 2019 due to the high prevalence of COPD in the U.S. On the other hand, in the Asia Pacific, the market is expected to showcase the fastest growth rate due to the improving primary care initiatives for early diagnosis and management of chronic lung diseases such as asthma and COPD

Nasal Drug Delivery Systems Market Worth $67.99 Billion By 2025

The global nasal drug delivery systems market size is expected to reach USD 67.99 billion by 2025 expanding at 6.5% CAGR, according to a new report by Grand View Research, Inc. Rising awareness about nasal products is one of the major factors driving the market. Growing geriatric population is also expected to have positive impact on the market. According to the United Nations Department of Economic and Social Affairs, the global geriatric population (60 years and above), was around 962 million in 2017. The number is expected to grow, particularly in Latin America with 71% rise in population aged 60 and over, followed by Asia (66%), Africa (64%), North America (41%), and Europe (23%).

Moreover, ongoing product development and their expected commercialization will propel market growth over the forecast period. For instance, In April 2018, Dr. Reddy’s Laboratories, along with its subsidiary Promius Pharma, LLC, announced filing of their New Drug Application (NDA) for DFN-02, for the treatment of migraine. Increasing adoption of self-administration practices and focus on other alternative routes of drug delivery, such as nasal drug delivery, also offer growth opportunities for the market. Some of the key companies in the industry are AstraZeneca PLC; OptiNose, Inc.; Pfizer, Inc.; Becton, Dickinson and Company; Promius Pharma LLC; B.F. Ascher & Company, Inc.; and Cadila Pharmaceuticals Ltd.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/nasal-drug-delivery-technology-system-market

Further key findings from the report suggest:

Nasal sprays led the dosage type segment in 2017 due to increased prevalence of asthma and other infectious diseases
On the other hand, nasal drops segment witnessed the fastest growth in 2017 owing to availability of cost-effective products with better efficacy
Non-pressurized containers segment led the market in 2017 due to continous development in nasal powders and gel products
Asthma was the dominant therapeutic application segment in 2017 and is estimated to be the fastest-growing segment with a CAGR of 7.0% during the forecast years due to increasing disease prevalence
Geographically, North America held the largest share in 2017. Asia Pacific is estimated to witness the fastest CAGR of 7.5% due to presence of key companies, such as Cipla Inc.
Some of the leading companies in the global nasal drug delivery technology market are GlaxoSmithKline PLC; AstraZeneca PLC; Pfizer, Inc.; OptiNose, Inc.; Becton, Dickinson and Company; Promius Pharma, LLC; Cadila Pharmaceuticals Ltd.; B.F. Ascher & Company, Inc.; PendoPharm, Inc.; Douglas Pharmaceuticals Ltd.; ENT Technologies Pty. Ltd.; and NAVEH Pharma Ltd.

Interleukin Inhibitors Market Worth $74.6 Billion By 2026

The global interleukin inhibitors market size is expected to reach USD 74.6 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 17.4% over the forecast period. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB’s bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn’s & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).

Click the link below:
https://www.grandviewresearch.com/industry-analysis/interleukin-inhibitors-market

Further key findings from the report suggest:

Psoriatic arthritis and IBD are projected to register fastest growth through to 2026
IL-17 is likely to overtake IL-23 as the leading type by 2026
IL-5 inhibitors for asthma to witness strong growth in the near future
Asia Pacific is expected to exhibit the fastest regional growth
Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration